Eli Lilly and Company (NYSE: LLY) has launched Zepbound® (tirzepatide) single-dose vials, available through its LillyDirect® self-pay channel, significantly expanding access to obesity treatment. These vials are priced at least 50% lower than other incretin (GLP-1) medicines for obesity, addressing the needs of patients who must self-pay, lack insurance coverage, or do not qualify for savings programs. The initiative aims to meet the growing demand for Zepbound while ensuring that patients receive genuine medication, avoiding the risks associated with counterfeit drugs.
The single-dose vials, available in 2.5 mg and 5 mg doses, are designed to broaden access to effective obesity treatment. In clinical studies, the 5 mg dose led to an average weight loss of 15% over 72 weeks. Zepbound, the first obesity treatment to activate both GIP and GLP-1 hormone receptors, addresses underlying causes of excess weight by reducing appetite and food intake.
Lilly's initiative reflects its commitment to addressing the chronic disease of obesity, often misclassified as a lifestyle choice, which leads to significant coverage gaps in healthcare. The new self-pay option not only provides a more affordable treatment but also ensures a transparent pricing structure by eliminating third-party supply chain entities. Additionally, Lilly continues to advocate for broader insurance coverage and policies that align with the scientific understanding of obesity as a serious chronic condition.
The single-dose vials, available in 2.5 mg and 5 mg doses, are designed to broaden access to effective obesity treatment. In clinical studies, the 5 mg dose led to an average weight loss of 15% over 72 weeks. Zepbound, the first obesity treatment to activate both GIP and GLP-1 hormone receptors, addresses underlying causes of excess weight by reducing appetite and food intake.
Lilly's initiative reflects its commitment to addressing the chronic disease of obesity, often misclassified as a lifestyle choice, which leads to significant coverage gaps in healthcare. The new self-pay option not only provides a more affordable treatment but also ensures a transparent pricing structure by eliminating third-party supply chain entities. Additionally, Lilly continues to advocate for broader insurance coverage and policies that align with the scientific understanding of obesity as a serious chronic condition.
